ESR1 and prostate cancer: In contradistinction to the overlap with HIF-binding sites in these cancers, the overlap with these tumour-associated transcription factors was significantly more than would be expected by chance in both cases; p = 3 × 10−4 for breast cancer-susceptibility loci and ER-binding sites, and p = 5 × 10−5 for prostate cancer-susceptibility loci and AR-binding sites.